Metastatic Gastro-esophageal Adenocarcinoma research hub

Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

This study looks at a new drug, bemarituzumab, combined with standard chemotherapy for advanced stomach or gastroesophageal junction cancer. It's for patients whose cancer has specific genetic markers (FGFR2b+) and who have had previous chemotherapy.